Skip to main content Skip to search Skip to main navigation

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.

The revision aims primarily to align the annexes with the latest version of the ICH Q3C guideline (up to Revision R9) and to further harmonise requirements between human and veterinary medicinal products. In addition, the update addresses practical challenges and ambiguities observed in regulatory assessment and inspections.

The changes concern Annex I only, while Annex II remains unchanged. A key new feature is the introduction of decision trees, intended to provide structured guidance on the control of residual solvents. These are designed to support consistent decision-making regarding when testing is required, when specifications need to be established, and how appropriate control strategies can be justified.

Furthermore, the revised annex includes more explicit expectations regarding the management of manufacturing changes, such as changes in starting materials, suppliers, or process parameters. In such cases, a more systematic assessment of the impact on residual solvents is required, including, where appropriate, revalidation activities.


Source:

EMA: Annexes to: EMA/CHMP/ICH/82260/2006 - ICH Q3C Guideline on impurities: guideline for residual solvents and EMA/CVMP/VICH/502/1999 - VICH GL18 Impurities: residual solvents in new veterinary medicinal products, active substances and excipients

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 15 Delayed

EMA: Revision of Annex 15 Delayed

In February 2026, the EMA published a concept paper on the revision of Annex 15 "Qualification and Validation" of the EU GMP Guide (we reported previously). The Agency has now released a corrected version containing a significantly revised timetable.
Read more
EU: Updated Q&A on Safety Features for Human Medicinal Products

EU: Updated Q&A on Safety Features for Human Medicinal Products

The European Commission has published Version 22 of its Questions and Answers on Safety Features for Medicinal Products for Human Use.
Read more
EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Here's the answer:
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
Previous
Next